Premium
Inhibition of estrogen‐stimulated growth of uterine leiomyomas by selective estrogen receptor modulators
Author(s) -
FuchsYoung Robin,
Howe Susan,
Hale Laura,
Miles Rebecca,
Walker Cheryl
Publication year - 1996
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/(sici)1098-2744(199611)17:3<151::aid-mc7>3.0.co;2-i
Subject(s) - raloxifene , selective estrogen receptor modulator , tamoxifen , estrogen , estrogen receptor , biology , medicine , uterine leiomyoma , endocrinology , leiomyoma , antiestrogen , cancer research , cell growth , uterus , cancer , breast cancer , pathology , biochemistry
Uterine leiomyoma is the most frequent gynecologic neoplasm in women. By using a panel of cell lines derived from spontaneous Eker rat leiomyomas, we examined the estrogen‐responsive phenotype of these tumor cells. Leiomyoma‐derived ELT cell lines proliferated in response to estrogen, and estrogen‐induced cell proliferation could be inhibited by the estrogen antagonist ICI 182780 and the selective estrogen‐receptor modulators (SERMs) raloxifene and tamoxifen. In addition to inhibiting cell growth, these antagonists also inhibited estrogen‐induced increases in progesterone‐receptor expression. These data indicate that SERMs such as raloxifene and tamoxifen act as estrogen antagonists in uterine myometrial cells and suggest that this class of compounds may be effective for treatment of this important gynecologic neoplasm. © 1996 Wiley‐Liss, Inc.